Some plans also require documentation of previous weight loss attempts through diet, exercise, or other interventions
With GLP-1based therapies, lower calorie intake, poor protein intake, inactivity, and rapid weight reduction can all contribute to lean-mass loss
Semaglutide, a selective GLP-1 receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, is one of the most extensively studied anti-obesity and anti-diabetes medications in history, with over 25,000 clinical trial participants and FDA approval for three distinct indications
How does retatrutide compare to tirzepatide and semaglutide in trials
While semaglutide remains highly effective, recent studies compared it to tirzepatide (Mounjaro for diabetes, Zepbound for obesity), a dual GIP/GLP-1 receptor agonist targeting two hormone receptors
doi: 10.1016/S0140-6736(21)01443-4 227 Committee ADAPP